Capricor Therapeutics Inc（CAPR）今日夜盘大涨5%，引起了市场的广泛关注。
消息面上，该公司宣布其实验性细胞疗法deramiocel在一项晚期试验中成功减缓了杜氏肌营养不良症（DMD）的发展速度。这一积极结果显著提升了投资者对该公司未来前景的信心。
此外，Capricor Therapeutics还启动了股票发行计划，尽管未披露具体规模，但公司表示募集资金将用于继续开发和生产候选产品，进一步推动了股价的上涨。
Capricor Therapeutics Inc（CAPR）今日夜盘大涨5%，引起了市场的广泛关注。
消息面上，该公司宣布其实验性细胞疗法deramiocel在一项晚期试验中成功减缓了杜氏肌营养不良症（DMD）的发展速度。这一积极结果显著提升了投资者对该公司未来前景的信心。
此外，Capricor Therapeutics还启动了股票发行计划，尽管未披露具体规模，但公司表示募集资金将用于继续开发和生产候选产品，进一步推动了股价的上涨。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.